抗肝癌生长技术在小鼠身上初获成功
(家庭医生医疗保健网杨阳报导)据美国达拉斯《商业快讯》报导，美国恩佐(Enzo)生物化学股份有限公司近日对外界宣称，其在以色列的研究组在一项临床前期动物实验中，使用该公司所生产的免疫调节产品-EHT899，成功地抑制了与乙型肝炎病毒有关的肝癌在实验小鼠身上的生长，并显著地降低了实验小鼠的死亡率。该公司的发言人说，这项成果对于肝癌以及人类其它恶性肿瘤的治疗将会有广阔的应用前景。
这项研究是由恩佐的科学家与以色列的有关人员，在位于耶路撒冷的哈达萨大学医学中心的肝病区内协作完成的。对与乙型肝炎病毒有关的肝癌的治疗，目前尚无理想的方法。在以往的研究中，哈达萨-恩佐研究小组已证实，口服EHT899可以增强机体抗乙型肝炎病毒的免疫反应。EHT899是恩佐公司研制开发的抗乙型肝炎病毒药物，目前正处于II期临床试验阶段。
该实验的研究人员向去胸腺小鼠(即失去免疫系统的小鼠)的体内注入人肝癌细胞，并于实验组小鼠的体内移植已由EHT899介导的小鼠免疫细胞，而于对照组小鼠的体内移植正常小鼠的免疫细胞(非EHT899介导)。结果显示，实验组小鼠体内的肿瘤全部停止生长，小鼠的死亡率显著降低；而对照组小鼠体内可观察到肿瘤的生长，最终所有对照组小鼠全部死亡。
, http://www.100md.com
恩佐公司行政副总裁L·恩格尔哈德特博士说，现在的研究证实，口服EHT899可以抑制人肝癌在实验小鼠身上的生长，直接导致实验小鼠对肿瘤免疫反应的增强。这项成果对人类肝癌的治疗将会有广阔的应用前景。下一步，他们将着手进行临床实验，以验证动物实验的结果。
Researchers Using Its Technology Successfully Suppressed Human Liver Cancer in Mice
Enzo Biochem Reports Researchers Using Its Technology Successfully Suppressed Human Liver Cancer in Mice Sees Significant Application for Treating Humans
DALLAS--(BUSINESS WIRE)--Oct. 30, 2000--Enzo Biochem, Inc., (NYSE:ENZ - news), reported today that in preclinical animal studies of the Company‘s proprietary immune regulation product, EHT899, researchers in Israel had achieved complete suppression of HBV-associated human liver cancer and significantly reduced mortality in laboratory mice. Enzo said that the studies may have significant potential application for treatment of liver and other cancers in humans.
, http://www.100md.com
The research results were presented in a paper delivered at a plenary session of the American Association for the Study of Liver Diseases meeting here this week. The study was conducted by researchers at the Liver Unit at the Hadassah University Medical Center in Jerusalem, Israel in collaboration with Enzo scientists.
There is currently no effective treatment for HBV-associated liver cancer. In previous studies, the Hadassah-Enzo team had shown that it is possible to augment an anti-HBV immune response by oral administration of EHT899, Enzo‘s proprietary medicine for HBV that is currently in a Phase II clinical trial.
, http://www.100md.com
``The present study has shown that the growth of human liver cancer in mice could be suppressed by oral administration of EHT899,‘‘ said Dean L. Engelhardt, Ph.D., Executive Vice President of Enzo. ``This procedure resulted in an enhanced immune response to the human tumor in the mice.‘‘
In these experiments, the researchers injected athymic mice (mice having no immune system) with human hepatoma (liver cancer) cells. The experimental mice were then transplanted with immune cells from donor mice that had been immune regulated by EHT899. The control mice were transplanted with immune cells from donor mice that had not been immune regulated. In the experimental mice that received the immune regulated cells, total suppression of the tumor was observed, along with significantly reduced mortality. In control mice transplanted with non immune regulated cells tumor growth occurred, leading to 100% mortality.
, http://www.100md.com
``Induction of oral immune regulation by EHT899 appears to enhance the anti-tumor immunological response, thus suppressing the growth of hepatocellular (liver) carcinoma in mice,‘‘ commented Dr. Engelhardt. ``These findings may have significant application for treatment of liver cancer in humans.‘
``Our next step is to consider clinical studies, given the strong results we observed in these animal experiments,‘‘ said Dr. Engelhardt. ``This research demonstrates the effective use of our immune regulation strategy in suppressing HBV-associated liver cancer. This hopeful development requires further exploration.‘‘, 百拇医药
这项研究是由恩佐的科学家与以色列的有关人员，在位于耶路撒冷的哈达萨大学医学中心的肝病区内协作完成的。对与乙型肝炎病毒有关的肝癌的治疗，目前尚无理想的方法。在以往的研究中，哈达萨-恩佐研究小组已证实，口服EHT899可以增强机体抗乙型肝炎病毒的免疫反应。EHT899是恩佐公司研制开发的抗乙型肝炎病毒药物，目前正处于II期临床试验阶段。
该实验的研究人员向去胸腺小鼠(即失去免疫系统的小鼠)的体内注入人肝癌细胞，并于实验组小鼠的体内移植已由EHT899介导的小鼠免疫细胞，而于对照组小鼠的体内移植正常小鼠的免疫细胞(非EHT899介导)。结果显示，实验组小鼠体内的肿瘤全部停止生长，小鼠的死亡率显著降低；而对照组小鼠体内可观察到肿瘤的生长，最终所有对照组小鼠全部死亡。
, http://www.100md.com
恩佐公司行政副总裁L·恩格尔哈德特博士说，现在的研究证实，口服EHT899可以抑制人肝癌在实验小鼠身上的生长，直接导致实验小鼠对肿瘤免疫反应的增强。这项成果对人类肝癌的治疗将会有广阔的应用前景。下一步，他们将着手进行临床实验，以验证动物实验的结果。
Researchers Using Its Technology Successfully Suppressed Human Liver Cancer in Mice
Enzo Biochem Reports Researchers Using Its Technology Successfully Suppressed Human Liver Cancer in Mice Sees Significant Application for Treating Humans
DALLAS--(BUSINESS WIRE)--Oct. 30, 2000--Enzo Biochem, Inc., (NYSE:ENZ - news), reported today that in preclinical animal studies of the Company‘s proprietary immune regulation product, EHT899, researchers in Israel had achieved complete suppression of HBV-associated human liver cancer and significantly reduced mortality in laboratory mice. Enzo said that the studies may have significant potential application for treatment of liver and other cancers in humans.
, http://www.100md.com
The research results were presented in a paper delivered at a plenary session of the American Association for the Study of Liver Diseases meeting here this week. The study was conducted by researchers at the Liver Unit at the Hadassah University Medical Center in Jerusalem, Israel in collaboration with Enzo scientists.
There is currently no effective treatment for HBV-associated liver cancer. In previous studies, the Hadassah-Enzo team had shown that it is possible to augment an anti-HBV immune response by oral administration of EHT899, Enzo‘s proprietary medicine for HBV that is currently in a Phase II clinical trial.
, http://www.100md.com
``The present study has shown that the growth of human liver cancer in mice could be suppressed by oral administration of EHT899,‘‘ said Dean L. Engelhardt, Ph.D., Executive Vice President of Enzo. ``This procedure resulted in an enhanced immune response to the human tumor in the mice.‘‘
In these experiments, the researchers injected athymic mice (mice having no immune system) with human hepatoma (liver cancer) cells. The experimental mice were then transplanted with immune cells from donor mice that had been immune regulated by EHT899. The control mice were transplanted with immune cells from donor mice that had not been immune regulated. In the experimental mice that received the immune regulated cells, total suppression of the tumor was observed, along with significantly reduced mortality. In control mice transplanted with non immune regulated cells tumor growth occurred, leading to 100% mortality.
, http://www.100md.com
``Induction of oral immune regulation by EHT899 appears to enhance the anti-tumor immunological response, thus suppressing the growth of hepatocellular (liver) carcinoma in mice,‘‘ commented Dr. Engelhardt. ``These findings may have significant application for treatment of liver cancer in humans.‘
``Our next step is to consider clinical studies, given the strong results we observed in these animal experiments,‘‘ said Dr. Engelhardt. ``This research demonstrates the effective use of our immune regulation strategy in suppressing HBV-associated liver cancer. This hopeful development requires further exploration.‘‘, 百拇医药